Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027960 (
mole
)
21,279
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We described the development of multiple melanocytic
nevi
within long-standing MF patches in four young patients. Mycosis fungoides (MF) patches are characterized by a regulatory-like
cytokine
profile leading to local immune suppression. The proliferation of nevomelanocytes is regulated by cellular senescence mechanisms mediated by immune system. The immunosuppressive effect of MF infiltrate in conjunction with the systemic effect of treatments may play a specific role in the nevomelanogenesis of the patients herein described.
...
PMID:Multiple melanocytic nevi restricted to mycosis fungoides patches in pediatric and young-adult patients. The potential role of local immunosuppression. 3065 26
Potential anti-inflammatory and anticarcinogenic effects of aspirin (ASA) may be suitable for melanoma chemoprevention, but defining biomarkers in relevant target tissues is prerequisite to performing randomized controlled chemoprevention trials. We conducted open-label studies with ASA in 53 human subjects with melanocytic
nevi
at increased risk for melanoma. In a pilot study, 12 subjects received a single dose (325 mg) of ASA; metabolites salicylate, salicylurate, and gentisic acid were detected in plasma after 4-8 h, and prostaglandin E2 (PGE
2
) was suppressed in both plasma and
nevi
for up to 24 h. Subsequently, 41 subjects received either 325 or 81 mg ASA (nonrandomized) daily for one week. ASA metabolites were consistently detected in plasma and
nevi
, and PGE
2
levels were significantly reduced in both plasma and
nevi
. Subchronic ASA dosing did not affect 5" adenosine monophosphate-activated protein kinase (AMPK) activation in
nevi
or leukocyte subsets in peripheral blood, although metabolomic and
cytokine
profiling of plasma revealed significant decreases in various (non-ASA-derived) metabolites and inflammatory cytokines. In summary, short courses of daily ASA reduce plasma and
nevus
PGE
2
and some metabolites and cytokines in plasma of human subjects at increased risk for melanoma. PGE
2
may be a useful biomarker in blood and
nevi
for prospective melanoma chemoprevention studies with ASA.
...
PMID:ASA Suppresses PGE
2
in Plasma and Melanocytic Nevi of Human Subjects at Increased Risk for Melanoma. 3190 19
<< Previous
1
2
3
